Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial

Study Questions:

Does the phosphodiesterase-5 (PDE-5) inhibitor sildenafil lead to improved exercise capacity and clinical status in patients with heart failure with preserved ejection fraction (HFPEF)?